Contrasting Cellectis (CLLS) & The Competition
Cellectis (NASDAQ: CLLS) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Cellectis to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
This is a summary of current recommendations and price targets for Cellectis and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cellectis presently has a consensus price target of $40.00, suggesting a potential upside of 31.62%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.40%. Given Cellectis’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectis is more favorable than its competitors.
This table compares Cellectis and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
14.8% of Cellectis shares are owned by institutional investors. Comparatively, 46.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Cellectis has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Cellectis’ competitors have a beta of 1.63, indicating that their average share price is 63% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cellectis and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cellectis||$49.49 million||-$78.63 million||-14.61|
|Cellectis Competitors||$207.78 million||-$2.31 million||0.68|
Cellectis’ competitors have higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Cellectis beats its competitors on 8 of the 12 factors compared.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.